Sign in
4

Changes in Ownership

Seres Therapeutics, Inc. Filed Acc 0000899243-17-016868

Options or other derivatives

  • Chief Technology Officer & EVP acquired 20,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Aunins John G. · Chief Technology Officer & EVP

Table II: Derivative

1 line
Date Transaction Shares Underlying Owned after D/I
2017-06-19 Grant or award : show line 1 in the form Restricted Stock Units +20,000 20,000 20,000 D
Loading xslF345X03/doc4.xml…